MISSION

The Group’s research aims to contribute to better patient management at various stages of head and neck cancer by promoting and validating new treatments and examining individual responses to therapies. Studies focus on area or locally advanced cancers such as salivary gland cancers that are recurrent and or metastatic.

PRACTICE CHANGING RESEARCH

  • Radiation Oncology Group

    EORTC 22791 – Phase III trial of twice daily fractions versus single daily fraction radiotherapy in oropharyngeal carcinoma.

    EORTC found that high-dose radiotherapy was better than low-dose at local control and prolonging survival in patients with advanced oropharyngeal cancers.

    READ MORE

  • Head & Neck Group

    EORTC 24891 – Is laryngeal preservation with induction chemotherapy safe in the treatment of hypopharyngeal squamous cell carcinoma?

    A randomized phase III trial.

    This landmark EORTC study found that larynx preservation treatment does not jeopardize overall survival in patients with squamous cell cancer of the head and neck. The results of this study changed standard of care and practice from larynx surgery to larynx-preserving radio-chemotherapy treatment, preserving natural speech and quality of life for these patients.

    READ MORE

  • Radiation Oncology Group

    EORTC 22851 – Phase III trial of open accelerated fractionation vs conventional fractionation in the radiotherapy of advanced head and neck carcinoma.

    EORTC found that accelerated radiotherapy (given over a shorter period of time), improves locoregional control for patients with head and neck squamous cell carcinomas and a poor prognosis.

    READ MORE

  • Head & Neck Group

    EORTC 22931 – Phase III randomized study on postoperative radio- and chemotherapy in patients with locally advanced head and neck carcinomas.

    Joint study of the EORTC Radiotherapy Cooperative Group and the Head and Neck Cancer Cooperative Group.

    This EORTC practice changing study, found chemotherapy plus radiotherapy after surgery is more effective than radiotherapy alone at treating locally advanced head and neck cancer. This then became the standard of care for treating this cancer.

    READ MORE

  • Head & Neck Group

    EORTC 24971 – A randomized phase III multicenter trial of neoadjuvant docetaxel (Taxotere) plus cisplatin plus 5-fluorouracil versus neoadjuvant cisplatin plus 5-fluorouracil in patients with locally advanced inoperable squamous cell carcinoma of the head and neck.

    EORTC compared two treatment regimens in patients with inoperable locoregionally advanced squamous cell carcinoma of the head and neck. It found that induction therapy by three chemotherapy drugs rather than two, followed by radiotherapy improved survival, reduced toxicity in patients and improved the overall health-related quality of life (HRQOL) of these patients.

    READ MORE

  • Dec-92
  • Jul-96
  • Aug-97
  • May-04
  • Oct-10

LATEST PUBLICATIONS

Want to read in detail our scientific findings on specific tumour type?
Search through our comprehensive list of EORTC published articles to date.

Search for an article
Sign up